Locations
Stockholm, Sweden · Stockholm, Sweden · Solna, Sweden
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2017
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
Something looks off?